Lorazepam

Generic Name: Lorazepam

Brand Names: Ativan, Loreev

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀Cl_₂N_₂O_₂

CAS Number: 846-49-1

Unique Ingredient Identifier: O26FZP769L

Background: Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication: Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions: Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus

Associated Therapies: Anesthetic premedication therapy

Clinical Trials

Biological Basis of Individual Variation in Social Cooperation

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Intranasal Vasopressin (AVP)
Drug: Intranasal Oxytocin (OT) 24 IU
Drug: Intranasal Vasopressin (AVP) 40 IU
Drug: Intranasal Placebo
Drug: Lorazepam

First Posted Date: 2012-03-29

Last Posted Date: 2017-09-25

Lead Sponsor: Emory University

Target Recruit Count: 707

Registration Number: NCT01566539

Locations: 🇺🇸
Emory University 1462 Clifton Rd, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

Resistance Under the Microscope

Phase 4

Completed

Conditions: Anxiety

Interventions: Drug: NaCl 0.9% (Sodium Chloride)
Drug: Lorazepam

First Posted Date: 2011-09-28

Last Posted Date: 2023-09-25

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 400

Registration Number: NCT01441843

Locations: 🇳🇱
Erasmus University Medical Center, Rotterdam, Netherlands

Developing Individualized Strategies to Prevent Nausea and Vomiting

Not Applicable

Withdrawn

Conditions: Postoperative Nausea and Vomiting
Genetic Polymorphisms

Interventions: Drug: Ondansetron
Drug: Lorazepam
Drug: Aprepitant

First Posted Date: 2011-07-13

Last Posted Date: 2013-11-14

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01393288

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 3 locations

Hydrocodone For Pain Control in First Trimester Surgical Abortion

Phase 4

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Hydrocodone/acetaminophen
Drug: Ibuprofen
Drug: Lorazepam
Drug: Lidocaine

First Posted Date: 2011-04-07

Last Posted Date: 2019-04-26

Lead Sponsor: Elizabeth Micks

Target Recruit Count: 121

Registration Number: NCT01330459

Locations: 🇺🇸
Planned Parenthood CW, Portland, Oregon, United States
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

A Study of the Effect of LY2216684 on Lorazepam

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: Placebo
Drug: Lorazepam

First Posted Date: 2011-01-12

Last Posted Date: 2019-03-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT01275144

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Leeds, United Kingdom